Med. praxi. 2019;16(4):215-219 | DOI: 10.36290/med.2019.032

Inflammatory bowel disease and the importance of probiotics treatment

MUDr. Barbora Pipek
Centrum péče o zažívací trakt, Vítkovická nemocnice, a. s., Ostrava
II. interní klinika – gastroenterologická a geriatrická, Fakultní nemocnice Olomouc

Crohn´s disease and ulcerative colitis are inflammatory bowel diseases, whose cause is not clear. We expected, that genetic and external factors participate in to their origin. The treatment of Crohn´s disease and ulcerative colitis is complicated and aminosalicylates, corticosteroids, immunosuppressants, and recently also biological therapy are the basis of the treatment of inflammatory bowel diseases (IBD). Probiotics are living microorganisms of the human origin, that can influence human health, if they are used in sufficient quantities. Their position in IBD treatment is not dominant, but they are important in the long-term treatment of ulcerative colitis and in prevention of pouchitis.

Keywords: inflammatory bowel disease, probiotics, intestinal microbiome, pouchitis

Published: October 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pipek B. Inflammatory bowel disease and the importance of probiotics treatment. Med. praxi. 2019;16(4):215-219. doi: 10.36290/med.2019.032.
Download citation

References

  1. Krejsek J. Přirozená mikrobiota člověka, obranné, metabolické a regulační funkce. Medicína po promoci. 2019; 20(1): 75-81.
  2. Jonkers D, Stockbrüger R. Review article: probiotics in gastrointestinal and liver diseases. Aliment Pharmacol Ther 2007; 26(Suppl. 2): 133-148. Go to original source... Go to PubMed...
  3. Lukáš M. Prebiotika, probiotika a střevní mikroflóra. Interní medicína pro praxi. 2015; 17(1): 14-17.
  4. Bortlik M. Probiotika v gastroenterologii. Remedia. 2009; 19(1): 47-51.
  5. Food and Agriculture Organization and World Health Organization Expert Consultation. Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Córdoba, Argentina: Food and Agriculture Organization of the United Nations and World Health Organization; 2001. [cited 2005 September 8].
  6. Zbořil a kol. Prebiotika a probiotika. In: Idiopatické střevní záněty. Praha: Mladá fronta a.s. 2018: 353-355.
  7. Rada V. Využitî probiotik, prebiotik a synbiotik. Medicina pro praxi. 2011; 8(1): 10-15.
  8. Frič P. Probiotics in Gastroenterology. Z Gastroenterol 2002; 40: 197-201. Go to original source... Go to PubMed...
  9. Lukas M. Mutaflor-Escherichia coli (Nissle 1917), sérotyp O6:K5:H1-nejlépe prozkoumané probiotikum současnosti. Gastroent Hepatol 2016; 70(3): 281-282. Go to original source...
  10. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305-309. Go to original source... Go to PubMed...
  11. Holubar SD, Cima RR, Sandborn WJ, et al. Treatment and prevention of pouchitis after ileal-pouch anal anastomosis for ulcerative colitis. Cochrane Database Syst Rev 2010; 6: CD001176 Go to original source... Go to PubMed...
  12. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108-114. Go to original source... Go to PubMed...
  13. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebocontrolled trial. Gastroenterology 2003; 124: 1202-1209. Go to original source... Go to PubMed...
  14. Pelech T, Frič P, Fixa B, et al. Srovnání Mutafloru a mesalazinu v udržovací léčbě neaktivní idiopatické proktokolitidy. Prakt Lék 1998; 78: 1998.
  15. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 1999; 354: 635-639. Go to original source... Go to PubMed...
  16. Kruis W, Frič P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine Gut 2004; 53: 1617-1623. Go to original source... Go to PubMed...
  17. Magro F, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. Journal of Crohn's and Colitis 2017; 11(6): 649-670. Go to original source... Go to PubMed...
  18. Derwa Y, et al. Efficacy of probiotics in inflammatory bowel disease: systematic review and meta-analysis. Journal of Crohn's and Colitis 2017; 11(Suppl. 1): S398-S399. Go to original source...
  19. Solovyeva O. Probiotics can extend remission of ulcerative colitis. Journal of Crohn's and Colitis 2014; 8(Supplement 1): S221. Go to original source...
  20. Lichtenstein, et al. The current place of probiotics in treatment of pouchitis: systematic review. Journal of Crohn's and Colitis 2017; 11(suppl 1): S321-S322. Go to original source...
  21. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's diseases J Clin Gastroenterol 1997; 25: 653-658. Go to original source... Go to PubMed...
  22. Fedorak RN, Feagan BG, Hotte N, et al. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease. Clin Gastroenterol Hepatol 2015; 13: 928-935. Go to original source... Go to PubMed...
  23. Fujimori S, et al. High dose probiotic and prebiotic cotherapy for remission induction of active Crohns disease. J Gastroenterol Hepatol 2007; 22: 1199-1204. Go to original source... Go to PubMed...
  24. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45: 1462-1464. Go to original source... Go to PubMed...
  25. Garcia Vilela E, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama Torres H, et al. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol 2008; 43: 842-848. Go to original source... Go to PubMed...
  26. Pantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn´s disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 52: 405-409. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.